Infant Bacterial Therapeutics AB (publ) (IBT.B)

Nasdaq Stockholm | Biotech | Pharmaceutical development for infants
Free
No email, no account, no signup.
Pulling latest news for Infant Bacterial Therapeutics AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Pharmaceutical development for infants
Market Cap
$79M
We're already tracking Infant Bacterial Therapeutics AB (publ) — here are the latest events we've registered

Recent News

  • On May 6, 2026, the company announced that ongoing discussions with the FDA indicate that existing clinical data may be sufficient to support a Biologics License Application (BLA) without the need for a post-marketing study. IBT is currently preparing for a pre-BLA meeting and subsequent regulatory filing later in 2026. Manufacturing validation processes are also progressing as planned for the upcoming submission.
Want to know how this news affects Infant Bacterial Therapeutics AB (publ)? Order the analysis.
Order analysis – $4.99

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Infant Bacterial Therapeutics AB (publ) will be delivered in the same format.
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
Infant Bacterial Therapeutics AB (publ) (IBT.B)
Fresh analysis on demand
Order analysis – $4.99
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.